PB-22: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
Line 1: Line 1:
'''PB-22''' is a [[synthetic cannabinoid]] that is used as an active ingredient in [[synthetic cannabis]] products. It was first identified in 2013 in samples of synthetic cannabis products sold in Japan. PB-22 is an analog of [[JWH-018]] which has a [[quinolinyl]] group, instead of a [[naphthoyl]] group. The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
{{DISPLAYTITLE:PB-22}}


==Chemistry==
== Overview ==
PB-22 is a derivative of [[JWH-018]], but instead of a [[naphthoyl]] group, it has a [[quinolinyl]] group. The structure of PB-22 is related to that of other synthetic cannabinoids, including [[AM-2201]], [[AM-694]], [[AM-1241]], and [[AM-2233]]. It is a white, crystalline powder that is soluble in organic solvents.
'''PB-22''' is a synthetic cannabinoid that has been used in scientific research and is often found in [[designer drugs]]. It is a potent agonist of the [[cannabinoid receptor]]s, which are part of the [[endocannabinoid system]]. PB-22 is structurally related to other synthetic cannabinoids and is known for its psychoactive effects.


==Pharmacology==
== Chemical Structure ==
The pharmacological properties of PB-22 are not well-studied. However, it is known to act as a potent [[agonist]] for the [[CB1 receptor]], with a [[Ki]] of 5.2 nM. This makes it roughly equivalent in potency to [[JWH-018]], although the effects in humans are not known.
PB-22 is classified as an indole-based synthetic cannabinoid. Its chemical structure includes a quinolin-8-yl ester linked to a pentyl chain. This structure is similar to other synthetic cannabinoids, such as [[JWH-018]] and [[AM-2201]].


==Legal status==
[[File:PB-22.png|thumb|right|Chemical structure of PB-22]]
PB-22 is a [[Schedule I controlled substance]] in the United States, and is also controlled in many other countries. It is illegal to manufacture, distribute, or possess PB-22 in these jurisdictions.


==See also==
== Pharmacology ==
PB-22 acts as a full agonist at the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] cannabinoid receptors. These receptors are part of the [[endocannabinoid system]], which plays a role in regulating various physiological processes, including mood, appetite, and pain sensation.
 
=== Mechanism of Action ===
The mechanism of action of PB-22 involves binding to the cannabinoid receptors, mimicking the effects of naturally occurring cannabinoids like [[tetrahydrocannabinol]] (THC). This binding leads to the activation of intracellular signaling pathways that result in the psychoactive and physiological effects associated with cannabinoid use.
 
== Legal Status ==
Due to its potential for abuse and lack of medical use, PB-22 has been classified as a controlled substance in many countries. It is often included in the list of substances banned under [[analogue drug laws]], which aim to control new psychoactive substances that are chemically similar to already controlled drugs.
 
== Health Effects ==
The use of PB-22 can lead to a range of health effects, both acute and chronic. Acute effects may include [[tachycardia]], [[anxiety]], [[paranoia]], and [[hallucinations]]. Chronic use can lead to dependence and withdrawal symptoms similar to those seen with other cannabinoids.
 
== Related Pages ==
* [[Synthetic cannabinoids]]
* [[Synthetic cannabinoids]]
* [[JWH-018]]
* [[Cannabinoid receptor]]
* [[AM-2201]]
* [[Endocannabinoid system]]
* [[Designer drugs]]


[[Category:Synthetic cannabinoids]]
[[Category:Synthetic cannabinoids]]
[[Category:Designer drugs]]
[[Category:Designer drugs]]
[[Category:Quinolines]]
[[Category:CB1 receptor agonists]]
{{stub}}

Latest revision as of 03:25, 13 February 2025


Overview[edit]

PB-22 is a synthetic cannabinoid that has been used in scientific research and is often found in designer drugs. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system. PB-22 is structurally related to other synthetic cannabinoids and is known for its psychoactive effects.

Chemical Structure[edit]

PB-22 is classified as an indole-based synthetic cannabinoid. Its chemical structure includes a quinolin-8-yl ester linked to a pentyl chain. This structure is similar to other synthetic cannabinoids, such as JWH-018 and AM-2201.

Chemical structure of PB-22

Pharmacology[edit]

PB-22 acts as a full agonist at the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes, including mood, appetite, and pain sensation.

Mechanism of Action[edit]

The mechanism of action of PB-22 involves binding to the cannabinoid receptors, mimicking the effects of naturally occurring cannabinoids like tetrahydrocannabinol (THC). This binding leads to the activation of intracellular signaling pathways that result in the psychoactive and physiological effects associated with cannabinoid use.

Legal Status[edit]

Due to its potential for abuse and lack of medical use, PB-22 has been classified as a controlled substance in many countries. It is often included in the list of substances banned under analogue drug laws, which aim to control new psychoactive substances that are chemically similar to already controlled drugs.

Health Effects[edit]

The use of PB-22 can lead to a range of health effects, both acute and chronic. Acute effects may include tachycardia, anxiety, paranoia, and hallucinations. Chronic use can lead to dependence and withdrawal symptoms similar to those seen with other cannabinoids.

Related Pages[edit]